Novartis to buy Avidity Biosciences for $12B, expands RNA drug development into neuromuscular diseases Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.

https://www.drugdiscoverynews.com/novartis-to-buy-avidity-biosciences-for-12b-expanding-rna-drug-development-into-neuromuscular-diseases-16761?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8CxsjH4rZKK0_vh8axC9CJ8c_J2G103xU_wflS35FDwMUCPm-OlyD11RcY1xZZjTXsOpmLHFTI21hxVmXIxMMTtgtLUg&_hsmi=391788877&utm_content=391788877&utm_source=hs_email